Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation
|
|
- Kristin Pearson
- 6 years ago
- Views:
Transcription
1 Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation ANIL K. BHANDARI, M.D, Director, Electrophysiology and EPS Fellowship Program Good Samaritan Hospital/ Harbor UCLA Medical Center, Los Angeles
2 AF and HF: Background and Status of the Problem Closely related and common conditions AF: 3-5 million in U.S. HF: 5-7 million in U.S. Share common etiologies: age, HTN, CAD, DM, sleep apnea, valvular disease, CKD Significant overlap in pathophysiology: each predispose to other Combination of both lead to deleterious hemodynamics ñ morbidity/mortality
3 Prevalence of AF in CHF Trials 50 Class IV 40 AF (%) Class I Class II-III Class II-III Class III 0 SOLVD-P SOLVD-T US CARVD ATLAS CONSENSUS CP
4 Interaction Between AF and HF Trulock et al., JACC 2014; 64: Action potential duration heterogeneity includes spatial and temporal non-uniformities ** This mechanistic hypothesis has fallen out of favor with recent evidence
5 Time to All-Cause Mortality in CHARM Based Upon EF and AF at Baseline Source: Olsson LG et al., Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program. JACC 47; , 2006
6 Prognostic Significance of Afib in Patients with HF Independent Predictor of Mortality Yes No 60 p=0.001 p=0.001 p=0.001 p=0.001 p=0.18 Sinus 50 AFib Mortality (%) Middlekauf (1991) Dries (1993) Crijns (2000) Mathew (2000) Carson (1993) Mahoney (1999) # Pts F/U (mos)
7 AF and HF: Restoration of Sinus will be Expected to Lead to: Improved hemodynamics and LVEF HF-related hospitalizations Stroke risk Improved survival Reversibility of HF in a select subset
8 Overview of Randomized Trials: Rate Control vs. Rhythm Control in A Fib Mortality Risk Thrombotic Stroke Risk Rate Control Rhythm Control Rate Control Rhythm Control
9 AF-CHF Trial 100 A. Death from Any Cause 100 B. Stroke NEJM 358:2667, No. at Risk Rhythm Control Rate Control 100 Hazard ratio, 0.97 (95% CI, ) P = 0.73 Rhythm Control Rate Control Months C. Worsening Heart Failure D. Composite Outcome No. at Risk Rhythm Control Rate Control Hazard ratio, 0.74 (95% CI, ) P = 0.32 Rhythm Control Rate Control Months No. at Risk Rhythm Control Rate Control Hazard ratio, 0.87 (95% CI, ) P = 0.17 Rhythm Control Rate Control Months No. at Risk Rhythm Control Rate Control Hazard ratio, 0.90 (95% CI, ) P = 0.20 Rhythm Control Rate Control Months
10 RF Catheter Ablation of AF First introduced in late 1990 Cures AF by eliminating and/or modifying AF sources in one or both atria Guidelines endorsed 1 st or 2 nd line Rx in symptomatic AF Success 3-4 fold higher in sinus restoration vs AADS: 80-90% paroxysmal 70-80% recent persistent AF 50-70% long lasting persistent AF Serious complications infrequent (1-2%) Not associated with adverse effects of AADs
11 Catheter Ablation of HF: Metanalysis Circ. Arrhythm Electrophysiol. 2014;7:
12 AF Catheter Ablation in Heart Failure: Meta Analysis 26 studies (mostly observational and small population) involving a total of 1838 patients Average F/U: 23 months (18-40 months) Efficacy for sinus maintenance: 60% (54-67%) Complication rate 4.2% Majority of the studies reported improvement in LVEF from 40% to 53% No meaningful data on morbidity or mortality benefit Anselmino et al., Circ. Arrhythm Electrolphysiol 2014;7:
13 Meta Analysis of AF Catheter Ablation in HF Anselmino et al., Circ. Arrhythm Electrolphysiol 2014;7:
14 2014 Guidelines-based Approach to AF in Heart Failure No evidence that rhythm control by AADs improves survival or LV dysfunction Routine use of rhythm-control strategy not recommended and rate control with anticoagulation preferred strategy Rhythm control indicated when: - symptoms persist despite rate control - rate control difficult to achieve - tachycardia-related CM suspected Catheter ablation role not adequately defined or studied
15 Recent Randomized Controlled Trials (RCTs) of Afib Catheter Ablation in Heart Failure RCT Year Published Addressed Question AATAC 2016 Is RF ablation superior to amiodarone for sinus maintenance in HF with AF? CAMERA-MRI 2017 Does AF catheter ablation improve LV dysfunction in patients with unexplained HF? CASTLE-AF 2018 Does catheter ablation improve mortality and morbidity in HF?
16 Patient Population in AATAC DiBiase et al., Circ. 2016;133:
17 Ablation vs. Amiodarone for Treatment of Persistent AF in CHF and Implanted ICD-AATACH Baseline Characteristic Catheter Ablation n=102 Amiodarone n=101 Age, yr 62 ± ± 11 AF duration, mo 9 ± 3 8 ± 4 LVEF, % 29 ± 5 30 ± 8 CAD, % ACE/ARB, % Beta blockers, % Left atrium, mm 47 ± 4 48 ± 5 DiBiase et al., Circ. 2016;133:
18 Freedom from AF (ICD documented) in AATACH DiBiase et al., Circ. 2016;133:
19 Other Outcome Analysis in AATACH Outcome Catheter Ablation Amiodarone P-value 2-yr Mortalaity, % All-cause Hospitalization, % LVEF, Δ, % QoL (MLFHQ score) DiBiase et al., Circ. 2016;133:
20 Catheter Ablation vs Medical Rate Control in AF and Systolic Dysfunction The CAMERA-MRI Study Prospective, multi-center, parallel group. Open label randomized trial ( ) Inclusion Criteria: Unexplained HF with persistent AF and EF <45% (Ischemic/valvular etiologies excluded) 4-week phase-in to control rate and optimize Rx Cardiac MRI (Gadolinium) at baseline and 6 months Primary endpoint: ΔLVEF at 6 months Secondary endpoints: MRI detected scar, BNP, 6 min walk, AF burden Prabhu et al., JACC 2017; 70:
21 AF Catheter Ablation in HF CAMERA-MRI Prabhu et al., JACC 2017; 70:
22 CAMERA-MRI Patient Characteristics Variable Prabhu et al., JACC 2017;70:1949 Catheter Ablation N = 33 Med Rx n=33 Age, yr AF History Duration, mo Previous Cardioversion, % Amiodarone failure, % HF History and AF Co-diagnosis, % AF preceded, % HF preceded, % Cardiac MRI LVEF, % Scar % ± ± 8 36 Echo LVEF, % 35 ± ± 9 Med Rx BB, % ACE/ARB, %
23 AF Catheter Ablation in HF CAMERA-MRI Prabhu et al., JACC 2017; 70:
24 CAMERA-MRI Outcomes at 6 Months Outcome Catheter Ablation N = 33 Med Rx n=33 P value Primary Endpoint Δ MRI-LVEF, % Secondary Endpoints Δ Echo-LVEF, % Δ Functional class Δ BNP Normal LVEF at 6 months, % Prabhu et al., JACC 2-17;70:
25 AF Catheter Ablation in HF CAMERA-MRI Prabhu et al., JACC 2017; 70:
26 Summary Statements of the CAMERA- MRI Study n Persistent AF is an under-recognized cause of otherwise unexplained sys HF (AF mediated CM) in a significant proportion of such pts n Sinus restoration with Catheter Ablation is associated with an improved LVEF, cardiac remodeling and functional capacity n Absence of MRI detected fibrosis identifies Super Responders to Catheter ablation
27 Catheter Ablation vs. Standard Therapy in Patients with LV Dysfunction and Atrial Fibrillation CASTLE-AF Multi-center, open-label, randomized trial ( ) Inclusion Criteria: - HF patients, with symptomatic paroxysmal/persistent AF - LVEF 35%, HF class II-IV - Implanted ICD/CRT (Biotronic) 5 weeks of phase-in period to adjust HF meds before randomizing 1:1 to catheter ablation vs med Rx Primary endpoint: Composite of all-cause mortality and HF-related hospitalizations Secondary endpoints: CVA, AF freedom, all-cause hospitalization Median F/U: 38 months Morrouche et al., NEJM 2018;378:
28 Patient Characteristics in CASTLE-AF Characteristic Ablation Treatment Type Medical Rx Number of patients Age, year HF Class II-III, % Etiology of HF Ischemic, % Non-ischemic, % Type of AF Paroxysmal, % Persistent, % Type of AF Median Range Amiodarone failure, % Morrouche et al., NEJM 2018;378:
29 Survival Curve for Primary Endpoint in CASTLE-AF Morrouche et al., NEJM 2018;378:
30 Survival Curve for Primary Endpoint in CASTLE-AF Morrouche et al., NEJM 2018;378:
31 Primary and Secondary Endpoints In CASTLE-AF Endpoint Ablation Treatment Type Medical Rx Hazard Ratio P value Primary 28% 45% Secondary Mortality HF hospital CV deaths CVA Other outcomes LVEF Δ over 5 yrs AF freedom 13% 21% 11% 3% 8% (2-19%) 63% 25% 36% 22% 6% 0.2% (-3 16%) 22% Morrouche et al., NEJM 2018;378:
32 Sub group Anaysis for Primary Endpoint In CASTLE-AF Morrouche et al., NEJM 2018;378:
33 AF and HF: Summary Statements and Implications RF catheter ablation restores sinus with 60-70% success rate Efficacy superior than amiodarone and maintained over longterm follow up Sinus restoration associated with total mortality, LVEF, HFrelated hospitalizations Non-ischemic etiology of HF, absence of MRI-detected scar and shorter AF duration predicts greater improvement in LVF and normalization of LV dysfunction in a select subset
34 Management of AF and HF in 2018 Guidelines endorsed Rate alone Rx (along with anticoagulation) likely to be an insufficient strategy AF catheter ablation approach should be considered earlier in the management It may prevent AF mediated CM in a subset and avoid the need for prophylactic ICD More prospective data ( e.g., CABANA) and Guidelines endorsement awaited
35 CABANA Trial Design Recent Onset AF Eligible for ablation and drug Rx 65 yr of age < 65 yr w / 1 CVA risk factor R Drug Rx Rate Rhythm w/ anticoagulation 1 ablation PVI WACA CFEGM GP Secondary analysis 1) NSR vs AF 2) ± underlying heart disease 3) AF type (parox, pers, perw) 4) DVC anticoagulation Discontinued AC R Continued AC
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice Walid Saliba, MD, FHRS Director, Atrial Fibrillation Center Director EP laboratory Heart and Vascular Institute Cleveland
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationAblation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation
Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor
More informationعلم االنسان ما لم يعلم
In the name of Allah, the Beneficiate, the Merciful ق ال هللا تعالي: 5 الدى علم بالق لم 4 علم االنسان ما لم يعلم سورة العلق It is He (Allah), Who has taught by the pen He has taught man which he did not
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationRole of Ablation of AF and PVCs in the Management of Heart Failure
Role of Ablation of AF and PVCs in the Management of Heart Failure Cara Pellegrini, MD, FHRS Acting Chief, Cardiology, SF VA Associate Professor of Medicine, UCSF Disclosures I have nothing to disclose
More informationFibrillazione atriale e scompenso: come interrompere il circolo vizioso.
Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationInterventional solutions for atrial fibrillation in patients with heart failure
Interventional solutions for atrial fibrillation in patients with heart failure Advances in Cardiovascular Arrhythmias Great Innovations in Cardiology Matteo Anselmino, MD PhD Division of Cardiology Department
More informationScompenso cardiaco e F A : ruolo della ablazione transcatetere. Prof. Fiorenzo Gaita
Scompenso cardiaco e F A : ruolo della ablazione transcatetere Prof. Fiorenzo Gaita Patients with atrial fibrillation (%) Prevalence of AF in HF Trials 60 50 30% NYHA III-IV NYHA IV 40 NYHA II-III 30 20
More informationRuolo della ablazione della fibrillazione atriale nello scompenso cardiaco
Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Matteo Anselmino Division of Cardiology Città della Salute e della Scienza Hospital University of Turin, Italy Disclosure: Honoraria
More informationAtrial Fibrillation: Catheter Ablation with New Technologies, Improving Quality of Life and Outcomes in Various Disease States
Atrial Fibrillation: Catheter Ablation with New Technologies, Improving Quality of Life and Outcomes in Various Disease States Srinivas R. Dukkipati, MD Co-Director, Cardiac Arrhythmia Service The Mount
More informationHow atrial fibrillation should be treated in the heart failure patient?
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 13/15 Ottobre 2016 How atrial fibrillation should be treated in the heart failure patient? Matteo Anselmino Dipartimento Scienze
More informationDipen Shah Cardiology Service, University Hospitals, Geneva Switzerland
Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland Disclosures Research Grants: Biosense Webster, St. Jude, Bard, Endosense, Biotronik Speakers Honoraria: Biosense Webster, Endosense,
More informationProgression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro
Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Jerónimo Farré MD, Madrid, ES AF: the kingdom of wishful thinking In AF we
More informationFirst question: Does CRT Work in AF?
CRT in AF Does it work and when to ablate AF versus AV node Maurizio Gasparini Chief EP and Pacing Unit Humanitas Research Hospital, Rozzano - Milano, Italy First question: Does CRT Work in AF? As any
More information2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist
2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist Todays Objectives Atrial Fibrillation evaluation and treatment from an EP perspective Multimodal
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationInteresting EP Cases Catheter ablation to treat congestive heart failure (CHF)
Interesting EP Cases Catheter ablation to treat congestive heart failure (CHF) Yiming WU, MD, PhD. Alaska heart and vascular institute. ywu@alaskaheart.com 907-561-3211 19 yo man transferred for out side
More informationWhat s new in my specialty?
What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationLong-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation
Long-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation Carlo Pappone, MD, PhD, FACC EP Director, Villa Maria Hospital Group How many times AF can increase mortality DO MORTALITY REALLY
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationRate vs. Rhythm Control in Atrial Fibrillation
Rate vs. Rhythm Control in Atrial Fibrillation Recent Perspectives Saeed Oraii MD Electrophysiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic Delirium Cordis First described by Sir
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationAtrial Fibrillation New Approaches, Techniques, and Technology
New Cardiovascular Horizons 2015 May 28, 2015 New Orleans, Louisiana Atrial Fibrillation New Approaches, Techniques, and Technology State of the Art - - 2015 Richard Abben, M D Director, Cardiac Arrhythmia
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationAtrial Fibrillation 2009
Atrial Fibrillation 2009 Michael Glikson, MD Director of Pacing & Electrophysiology Leviev Heart Center Sheba medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center Rhythm vs rate control
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationΚατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ.
Κατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ» Rhythm control antiarrhythmic drugs vs catheter ablation Summary
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationPossible clinical and hemodynamic predictors of atrial fibrillation recurrence after catheter ablation
Samara Regional Center of Cardiosurgery Possible clinical and hemodynamic predictors of atrial fibrillation recurrence after catheter ablation S. Dolginina, S. Garkina, S. Khokhlunov, D. Duplyakov Russia
More informationJay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center
Jay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center A-Fib Facts Yes, you may be able to blame your parents It is more of a nuisance than a
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationPRIMARY RESULTS OF RF CATHETER ABLATION FOR AF IN VIETNAM HEART INSTITUTE. PHAM QUOC KHANH, MD, PhD. et al Vietnam Heart Institute
PRIMARY RESULTS OF RF CATHETER ABLATION FOR AF IN VIETNAM HEART INSTITUTE PHAM QUOC KHANH, MD, PhD. et al Vietnam Heart Institute Background - Forms of Atrial Fibrillation - Clinical type of AF: + paroxysmal
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationHow Should we Select Patients for Catheter Ablation? Douglas Esberg, MD, FHRS
How Should we Select Patients for Catheter Ablation? Douglas Esberg, MD, FHRS November 2, 2018 2 3 4 5 Atrial Flutter Typical isthmus dependent flutter Success rate ~95% Complications 1% (mostly groin
More informationCatheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) Trial
Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) Trial Douglas L. Packer MD, Kerry L. Lee PhD, Daniel B. Mark MD, MPH, Richard A. Robb PhD for the CABANA Investigators Mayo
More informationThe Role of ACEI and ARBs in AF prevention
The Role of ACEI and ARBs in AF prevention Dr. Sameh Shaheen MD, FESC Prof. of cardiology Ain-Shams university Time course of atrial substrate remodeling in relation to the clinical appearance of AF and
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationAblation of persistent AF Is it different than paroxysmal?
Ablation of persistent AF Is it different than paroxysmal? Steven J. Kalbfleisch, MD Medical Director Electrophysiology Laboratory Ohio State University Wexner Medical Center Ross Heart Hospital Columbus,
More informationAtrial Fibrillation and Heart Failure
Date Clinical Title Atrial Fibrillation and Heart Failure Raul Weiss MD, FAHA, FACC, FHRS and CCDS Director, Electrophysiology Fellowship Program Professor of Medicine The Ohio State University Wexner
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationCatheter Ablation of Recurrent Ventricular Tachycardia Should Be Done Before Antiarrhythmic Therapy with Amiodarone is Tried CONTRA
Catheter Ablation of Recurrent Ventricular Tachycardia Should Be Done Before Antiarrhythmic Therapy with Amiodarone is Tried CONTRA Erik Wissner, MD, F.A.C.C. Director - Magnetic Navigation Laboratory
More informationTreatment of atrial fibrillation in patients with advanced heart failure - Rhythm or rate control: how to decide?
Treatment of atrial fibrillation in patients with advanced heart failure - Rhythm or rate control: how to decide? Uta C. Hoppe Dep. of Internal Medicine III University of Cologne No conflict of interest
More informationDoes AF Ablation Lower Stroke Risk? Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions
Does AF Ablation Lower Stroke Risk? Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions Relationships! Consultant: Medtronic, St Jude, Atricure, Boherringer
More informationBi-Ventricular pacing after the most recent studies
Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda
More informationCLINICAL OUTCOME OF AF ABLATION Who Benefits from Catheter Ablation?? Dr Gamal Shaban MD FESC Fellow of EHRA ECR AFA AFIB ALLIANCE NHI
CLINICAL OUTCOME OF AF ABLATION Who Benefits from Catheter Ablation?? Dr Gamal Shaban MD FESC Fellow of EHRA ECR AFA AFIB ALLIANCE NHI RHYTHM IS THE SOUL OF LIFE AF the last remaining challenge Considerable
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationAtrial fibrillation: Who should be referred for ablation therapy for atrial fibrillation?. September 12 th, 2015
Atrial fibrillation: Who should be referred for ablation therapy for atrial fibrillation?. September 12 th, 2015 MMMMMMM MMMMMMM MMMMMMM Sohail Hassan MD FACC, FHRS Director, Cardiac Electrophysiology
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationManagement of atrial fibrillation in heart failure
Nationale hartfalendag 2017 Zeist Management of atrial fibrillation in heart failure Isabelle C Van Gelder University of Groningen University Medical Center Groningen The Netherlands Disclosures Grant
More informationState of the Art Management on Atrial Fibrillation in Monica Lo, MD, FACC, FHRS April 15, 2016
State of the Art Management on Atrial Fibrillation in 2016 Monica Lo, MD, FACC, FHRS April 15, 2016 Scope of the Problem More than 30 million people worldwide 1 5 million new cases each year 1 in 4 lifetime
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationWho Gets Atrial Fibrilla9on..?
Birmingham October 20 th 2013 AFA Pa9ents Day Symptoma9c Atrial Fibrilla9on What therapies are available? GENERAL BACKGROUND Andrew Grace Papworth Hospital and University of Cambridge Consultant: Medtronic
More informationModifiable Up-Stream Risk Factors:
Modifiable Up-Stream Risk Factors: Recent Studies in AF Prevention Behzad Pavri, MD, FACC, FHRS Professor of Medicine Director, CCEP Fellowship Thomas Jefferson University Hospital, Philadelphia, USA Disclosures
More informationFA et Apnée du Sommeil
FA et Apnée du Sommeil La Réunion Octobre 2017 Pascal Defaye CHU Grenoble-Alpes Obstructive Sleep Apnea and AF Incidence of atrial fibrillation (AF), based on presence or absence of OSA. Cumulative frequency
More informationβ 1 Adrenergic Receptor Polymorphism-Dependent Differences
GENETIC-AF Phase II Trial of Pharmacogenetic Guided Beta-Blocker Therapy with Bucindolol vs. Metoprolol for the Prevention of Atrial Fibrillation/Flutter in Heart Failure William T. Abraham, MD Professor
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More information3/23/2018. Complications of VAD Therapy: Arrhythmias. Disclosures. Agenda. I have no relevant disclosures
March 23, 2018 Complications of VAD Therapy: Arrhythmias Sandeep M. Jani, MD, MPH Associate Directory of Advanced Heart Failure and Population Health MedStar Heart and Vascular Institute - Baltimore Sandeep
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More information'Understanding Atrial Fibrillation: New Insights in Pathophysiology
82 nd Annual Scientific Meeting of the Japanese Circulation Society Osaka 2018 'Understanding Atrial Fibrillation: New Insights in Pathophysiology Barbara Casadei, MD DPhil FMedSci FESC British Heart Foundation
More informationManagement Options for Atrial Fibrillation. Evidence Review Group Meeting Massachusetts General Hospital Boston, MA
Management Options for Atrial Fibrillation Evidence Review Group Meeting Massachusetts General Hospital Boston, MA July 16, 2010 Agenda for the Day Introductions and potential influences on judgment Systematic
More informationHeart Failure and Atrial Fibrillation
Heart Failure and Atrial Fibrillation 신미승 가천의대심장내과 Prevalence of AF & CHF AF : the most common cardiac arrhythmia more than 2.2 million Americans -- 2007 ACC CHF : more than 5 million Americans The prevalence
More informationStand alone maze: when and how?
Stand alone maze: when and how? Dong Seop Jeong Department of Thoracic and Cardiovascular Surgery, HVSI Samsung Medical Center Type of atrial fibrillation First diagnose AF Paroxysmal AF: self-terminating
More informationBiatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD
Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD Disclosures Consultant/Speaker AtriCure Medtronic CryoLife Edwards Abbott Research Funding Abbott Equity Interest Clear Catheter Cleveland Clinic
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationOutcomes of AF Ablation
2017 춘계심혈관통합학술대회 AF Summit: Atrial Fibrillation Apr.21(Fri) 14:40-16:10 Rm.300B 15:00-15:10 Outcomes of AF Ablation Gi-Byoung Nam MD Asan Medical Center, UUCM 2017 Annual Spring Scientific Conference of
More informationAF ABLATION Concepts and Techniques
AF ABLATION Concepts and Techniques Antony F Chu, M.D. Director of Complex Ablation Arrhythmia Services Section Division of Cardiology at the Rhode Island and Miriam Hospital HIGHLIGHTS The main indications
More informationPVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.
PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?
More informationRate Control versus Rhythm Control in NSTEMI
Rate Control versus Rhythm Control in NSTEMI Gulmira Kudaiberdieva, MD, FESC Adana, Turkey Conflict of interest: None to declare Istanbul - 2012 OUTLINE Significance of AF in ACS Prognostic value of AF
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationModest Medtronic. Modest Boehringer Ingelheim
Adults With AF (millions) Modest Medtronic Modest Boehringer Ingelheim Changing Modalities of Care for Atrial Fibrillation Jill Repoley MSN, CRNP, CCDS, CEPS, FHRS 7 6 5 4 3 2 1 2.08 2.26 2.44 2.66 2.94
More informationMission Statement for our Arrhythmia Care
Mission Statement for our Arrhythmia Care We are dedicated to provide a compassionate and an outstanding care for patients with cardiac arrhythmias. We will be utilizing the cutting edge and the most advanced
More informationCATHETER ABLATION FOR ATRIAL FIBRILLATION WHEN and HOW
CATHETER ABLATION FOR ATRIAL FIBRILLATION WHEN and HOW Carlo Pappone, MD, PhD, FACC San Raffaele University Hospital, Milan, Italy ATRIAL FIBRILLATION FOR CLINICIANS FIRST DETECTED PAROXYSMAL PERMANENT
More informationConcept, Challenges, Uptake and Adoption of Atrial Fibrillation Ablation: An Academic View. Douglas L. Packer MD Silver Springs, MD April 27, 2009
Concept, Challenges, Uptake and Adoption of Atrial Fibrillation Ablation: An Academic View Douglas L. Packer MD Silver Springs, MD April 27, 2009 Presenter Disclosure Information Catheter Ablation for
More informationDiastolic Heart Failure Uri Elkayam, MD
Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A
More informationCatheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD
Catheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD Taipei Veterans General Hospital, Taiwan Outline of AF Ablation 1. Strategy for Catheter Ablation of AF 2. Substrate
More informationNEWLY DETECTED ATRIAL FIBRILLATION. Edgar S. Carell, M.D. Director, Vascular Medicine Clinic West Suburban Cardiology
NEWLY DETECTED ATRIAL FIBRILLATION Edgar S. Carell, M.D. Director, Vascular Medicine Clinic West Suburban Cardiology 68 y/o woman complains of - generalized fatigue - mild DOE - never eats but keeps gaining
More informationHigh density substrate mapping In AF
High density substrate mapping In AF A Pisapia J Seitz C Bars M Bremondy A Ferracci * J Khalifa ** * St Joseph Hospital Marseille ** Ann Arbor University Turin 2016 Hôpital Saint Joseph Marseille jseitz@hopital-saint-joseph.fr
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationIndicatie voor ablatie bij voorkamerfibrillatie. Andrea Sarkozy Cardiologie Universitair Ziekenhuis Antwerpen
Indicatie voor ablatie bij voorkamerfibrillatie Andrea Sarkozy Cardiologie Universitair Ziekenhuis Antwerpen Definition and Classification of AF - Practical aspects Classification of AF Paroxysmal, persistent,
More informationA Cryo Anatomical Procedure to Everyone? Saverio Iacopino, FACC, FESC
A Cryo Anatomical Procedure to Everyone? Saverio Iacopino, FACC, FESC AF Clinical/Referral Challenge Asymptomatic 40% 3 Rx Effective 30% Failed Rx Ablation Atrial fibrillation (AF) is the most common Candidate
More informationHeart Failure and Atrial Fibrillation. Stephen Wilton ACC Rockies Banff March 15, 2016
Heart Failure and Atrial Fibrillation Stephen Wilton ACC Rockies Banff March 15, 2016 Disclosures Research funding: St. Jude Medical Consulting / Honoraria Boehringer Ingelheim Arca Biopharma Key Points
More informationChronic Primary Mitral Regurgitation
Chronic Primary Mitral Regurgitation The Case For Early Surgical Intervention William K. Freeman, MD, FACC, FASE DISCLOSURES Relevant Financial Relationship(s) None Off Label Usage None Watchful Waiting......
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationCombined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation
Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation Giulio Molon, MD FACC, FESC, Fellow ANMCO Card Dept, S.Cuore hospital Negrar
More informationCardiac Resynchronization Therapy. Michelle Khoo, MD
Cardiac Resynchronization Therapy Michelle Khoo, MD 10.7.08 HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations SD in Competitive Athletes
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationAtrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder University Medical Center Groningen
Atrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder The Netherlands Madrid Europace June 2011 Conflict of interests Research grants from Medtronic, SJM, Biotronik, Boston,
More informationTehran Arrhythmia Center
Tehran Arrhythmia Center The Worst Scenario A 4 year old kid High heart rates first noted by parents at 20 months of age. Family physician detected rates as high as 220 bpm at that age. He was visited,
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationSurgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan
Surgical AF Ablation : Lesion Sets and Energy Sources What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan Disclosures Consultant/Advisory Board: Abbott, Edwards Lifesciences
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationIs cardioversion old hat? What is new in interventional treatment of AF symptoms?
Is cardioversion old hat? What is new in interventional treatment of AF symptoms? Joseph de Bono Consultant Electrophysiologist University Hospitals Birmingham Atrial Fibrillation (AF) Affects 2% of the
More information